1461084418-1039de9d-bda0-45aa-a9d6-12eef8176b3d

1. Apparatus adapted to supply multiple foam machines with foam precursor chemicals, said apparatus comprising:
a first tote having a top opening and a bottom drain and containing a first foam precursor chemical,
a second tote having a top opening and a bottom drain and containing a second foam precursor chemical,
a first supply line connected to said bottom drain of said first tote and in fluid communication with a first set of batcher stands,
a second supply line connected to said bottom drain of said second tote and in fluid communication with a second set of batcher stands,
a first set of batcher pumps each of which is positioned in a respective one of said first set of batcher stands, and
a second set of batcher pumps each of which is positioned in a respective one of said second set of batcher stands,
each said batcher pump of said first and second sets of batcher pumps adapted to be in fluid communication with a respective one of the foam machines.
2. The apparatus of claim 1 wherein said batcher stands are supported on said totes.
3. The apparatus of claim 1 wherein said batcher stands are free standing and are positioned remote from said totes.
4. The apparatus of claim 1 wherein said batcher stands are upstanding cylindrical tubes.
5. The apparatus of claim 1 wherein said batcher stands of said first set of batcher stands are connected in series and said batcher stands of said second set of batcher stands are connected in series.
6. The apparatus of claim 5 wherein each said batcher stand has a valve to permit or prevent chemical from entering said each batcher stand.
7. The apparatus of claim 1 wherein said batcher stands of said first set of batcher stands have a first common base and wherein said batcher stands of said second set of batcher stands have a second common base.
8. The apparatus of claim 1 further comprising first and second quick connect fittings connected between said drain ports of said first and second totes and said first and second supply lines, respectively.
9. Apparatus for manufacturing foam cushions, said apparatus comprising:
a first foam machine,
at least a second foam machine,
a first tote having a top opening and a bottom drain and containing a first foam precursor chemical,
a second tote having a top opening and a bottom drain and containing a second foam precursor chemical,
a first supply line connected to said bottom drain of said first tote and in fluid communication with a first set of batcher stands,
a second supply line connected to said bottom drain of said second tote and in fluid communication with a second set of batcher stands,
a first set of batcher pumps each of which is positioned in a respective one of said first set of batcher stands, and
a second set of batcher pumps each of which is positioned in a respective one of said second set of batcher stands,
each said batcher pump of said first and second sets of batcher pumps in fluid communication with a respective one of said foam machines.
10. The apparatus of claim 9 wherein said batcher stands are supported on said totes.
11. The apparatus of claim 9 wherein said batcher stands are free standing and are positioned remote from said totes.
12. The apparatus of claim 9 wherein said batcher stands are upstanding cylindrical tubes.
13. The apparatus of claim 9 wherein said batcher stands of said first set of batcher stands are connected in series and said batcher stands of said second set of batcher stands are connected in series.
14. The apparatus of claim 13 wherein each said batcher stand has a valve to permit or prevent chemical from entering said each batcher stand.
15. The apparatus of claim 9 wherein said batcher stands of said first set of batcher stands have a first common base and wherein said batcher stands of said second set of batcher stands have a second common base.
16. The apparatus of claim 9 further comprising first and second quick connect fittings connected between said drain ports of said first and second totes and said first and second supply lines, respectively.
17. The apparatus of claim 9 wherein said foam machines are foam-in-bag machines.
18. The apparatus of claim 9 wherein said foam machines are foam-in-place machines.
19. Apparatus adapted to supply a foam machine with a foam precursor chemical, said apparatus comprising:
a tote having a top opening and a bottom drain and containing a foam precursor chemical,
a supply line connected to said bottom drain of said tote and in fluid communication with a batcher stand, and
a batcher pump positioned in said batcher stand,
said batcher pump adapted to be in fluid communication with the foam machine.
20. The apparatus of claim 19 wherein said batcher stand is supported on said tote.
21. The apparatus of claim 19 wherein said batcher stand is free standing and is positioned remote from said tote.
22. The apparatus of claim 19 wherein said batcher stand is an upstanding cylindrical tube.
23. The apparatus of claim 22 wherein said batcher stand has a valve to permit or prevent chemical from entering said batcher stand.
24. The apparatus of claim 19 further comprising a quick connect fitting connected between said drain port and said supply line.
25. Apparatus for manufacturing foam cushions, said apparatus comprising:
a foam machine,
a tote having a top opening and a bottom drain and containing a foam precursor chemical,
a supply line connected to said bottom drain of said tote and in fluid communication with a batcher stand, and
a batcher pump positioned in said batcher stand,
said batcher pump in fluid communication with said foam machine.
26. The apparatus of claim 25 wherein said batcher stand is supported on said tote.
27. The apparatus of claim 25 wherein said batcher stand is free standing and is positioned remote from said tote.
28. The apparatus of claim 25 wherein said batcher stand is an upstanding cylindrical tube.
29. The apparatus of claim 28 wherein said batcher stand has a valve to permit or prevent chemical from entering said batcher stand.
30. The apparatus of claim 25 further comprising a quick connect fitting connected between said drain port and said supply line.
31. The apparatus of claim 25 wherein said foam machine is a foam-in-bag machine.
32. The apparatus of claim 25 wherein said foam machine is a foam-in-place machine.
33. A method of supplying a foam precursor chemical from a container to a pump of a foam machine, comprising the steps of:
providing a container having a top opening and a bottom drain,
providing an upstanding cylindrical tube having a closed bottom and an open top,
connecting a supply line to the bottom drain of the container and to the cylindrical tube near a bottom of the cylindrical tube such that an interior of the cylindrical tube and the container are in fluid communication, and
inserting a pump into the open top of the cylindrical tube.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A circuit substrate comprising:
a substrate;
an insulating coating layered structure formed on said substrate, having top and bottom surfaces, and formed with a patterned recess that is indented inwardly from said top surface, that is disposed above said bottom surface, and that is defined by a recess-defining wall, said recess-defining wall having a bottom wall portion and a surrounding wall portion that extends upwardly from a periphery of said bottom wall portion; and
a patterned metallic layered structure including an electroless plating metal layer formed on said bottom wall portion of said recess-defining wall.
2. The circuit substrate of claim 1, wherein said bottom wall portion is roughened by laser or plasma ablation so as to enhance the bonding between said electroless plating metal layer and said bottom wall portion.
3. The circuit substrate of claim 1, wherein said electroless plating metal layer is disposed within said patterned recess and is spaced apart from said surrounding wall portion of said recess-defining wall by a spacing.
4. The circuit substrate of claim 1, wherein said electroless plating metal layer contains an active metal selected from the group consisting of palladium, rhodium, platinum, iridium, osmium, gold, nickel, iron, and combinations thereof.
5. The circuit substrate of claim 4, wherein said electroless plating metal layer further contains a first metal different from said active metal and selected from the group consisting of copper, nickel, silver, and gold.
6. The circuit substrate of claim 1, wherein said patterned metallic layered structure further includes an electroplating metal layer formed on said electroless plating metal layer.
7. The circuit substrate of claim 6, wherein said electroplating metal layer includes first and second metal sub-layers, said first metal sub-layer being formed on said electroless plating metal layer, said second metal sub-layer being formed on said first metal sub-layer.
8. The circuit substrate of claim 1, wherein said insulating coating layered structure includes a middle coating layer and an upper coating layer formed on said middle coating layer and defining said top surface of said insulating coating layered structure, said patterned recess extending from said top surface through said upper coating layer and having a bottom side that is confined by said middle coating layer, said upper coating layer having a dark color, said middle coating layer having a light color, said electroless plating metal layer being formed on said middle coating layer.
9. The circuit substrate of claim 8, wherein said insulating coating layered structure further includes a lower coating layer formed on said substrate, said middle coating layer being formed on said lower coating layer.
10. The circuit substrate of claim 1, wherein said substrate is transparent.
11. A method for making a circuit substrate, comprising:
providing a substrate;
forming an insulating coating layered structure on the substrate, the insulating coating layered structure having a top surface;
forming a patterned recess in the insulating coating layered structure such that the patterned recess is indented inwardly from the top surface, the patterned recess being defined by a recess-defining wall having a bottom wall portion and a surrounding wall portion extending upwardly from the bottom wall portion; and
forming an electroless plating active layer on the recess-defining wall of the patterned recess and on the top surface of the insulating coating layered structure.
12. The method of claim 11, wherein said bottom wall portion is roughened by laser or plasma ablation so as to enhance the bonding between said electroless plating active layer and said bottom wall portion.
13. The method of claim 11, further comprising removing a portion of the electroless plating active layer that is disposed along a peripheral edge of the bottom wall portion of the recess-defining wall so as to form the electroless plating active layer into a first region which is disposed on the bottom wall portion, and a second region which is spaced apart from the first region.
14. The method of claim 13, further comprising electroplating an electroplating metal layer on the first region of the electroless plating active layer.
15. The method of claim 11, wherein the patterned recess is formed by laser or plasma ablation.
16. The method of claim 15, wherein the insulating coating layered structure includes a middle coating layer and an upper coating layer formed on the middle coating layer and defining the top surface of the insulating coating layered structure, the patterned recess extending from the top surface through the upper coating layer and having a bottom side that is confined by the middle coating layer, the upper coating layer having a dark color, the middle coating layer having a light color.
17. The method of claim 16, wherein the insulating coating layered structure further includes a lower coating layer formed on the substrate, the middle coating layer being formed on the lower coating layer.
18. The method of claim 14, further comprising removing the second region of the electroless plating active layer from the top surface of the insulating coating layered structure after the step of electroplating the electroplating metal layer on the first region of the electroless plating active layer.

1461084407-047f483e-6c48-4a56-b3e0-36811f9b5c48

What is claimed is:

1. A method of regenerating a mesenchymally-derived tissue, comprising contacting said tissue with a composition comprising an isolated adult mesenchymal stem cell, said mesenchymal stem cell comprising an exogenous nucleic acid encoding an akt gene.
2. The method of claim 1, wherein said tissue is selected from the group consisting of connective tissue, epithelial tissue, nervous tissue and muscle tissue.
3. The method of claim 1, wherein said tissue is selected from the group consisting of myocardial, brain, spinal cord, bone, cartilage, liver, muscle, lung, vascular, and adipose tissue.
4. The method of claim 2, wherein said muscle tissue comprises skeletal muscle.
5. The method of claim 2, wherein said muscle tissue comprises smooth muscle.
6. The method of claim 1, wherein said mesenchymal stem cell further comprises an exogenous nucleic acid encoding a homing molecule.
7. The method of claim 6, wherien said homing molecule is selected from the group consisting of a chemokine receptor, an interleukin receptor, an estrogen receptor, an integrin receptor
8. The method of claim 1, wherein said mesenchymal stem cell further comprises an exogenous nucleic acid encoding a hormone.
9. The method of claim 1, wherein said mesenchymal stem cell further comprises an exogenous nucleic acid encoding an angiogenic factor.
10. The method of claim 1, wherein said mesenchymal stem cell further comprises an exogenous nucleic acid encoding a bone morphogenetic protein.
11. The method of claim 1, wherein said mesenchymal stem cell further comprises an exogenogenous nucleic acid encoding an extracellular matrix protein.
12. The method of claim 1, wherein said mesenchymal stem cell further comprises an exogenous nucleic acid encoding a cytokine or growth factor.
13. A composition comprising an apoptosis-resistant primary stem cell, said stem cell comprising an exogenous akt gene, wherein apoptosis of said cell is reduced by at least 10% compared to a primary mesenchymal stem cell lacking said akt gene.
14. The composition of claim 13, wherein said stem cell is an adult bone-marrow derived mesenchymal cell.
15. The composition of claim 13, wherein said apoptosis is reduced by at least 50%.
16. The composition of claim 13, wherein said apoptosis is reduced by at least 2-fold.
17. The composition of claim 13, wherein said apoptosis is reduced by at least 5-fold.
18. The composition of claim 13, wherein said apoptosis is reduced by at least 10-fold.
19. The composition of claim 13, wherein said stem cell is non-tumor forming.
20. The composition of claim 13, wherein said stem cell further comprises a homing receptor.
21. A method of regenerating an injured myocardial tissue, said method comprising contacting said tissue with the composition comprising an isolated adult recombinant mesenchymal stem cell (rMSC), said rMSC comprising an exogenous nucleic acid operably linked to a promoter, wherein said nucleic acid expresses a therapeutically effective amount of an anti-apoptotic gene.
22. The method of claim 21 wherein said mesenchymal stem cells are administered to an individual to regenerate or repair cardiac muscle that has been damaged through disease.
23. The method of claim 22 wherein said mesenchymal stem cells are administered to an individual who has suffered myocardial infarction.
24. The method of claim 22 wherein said mesenchymal stem cells are administered directly to the heart.
25. The method of claim 22 wherein said mesenchymal stem cells are administered systemically.
26. The method of claim 25 wherein said mesenchymal stem cells are administered by injection.
27. The method of claim 22 wherein said mesenchymal stem cells are human.
28. The method of claim 27 wherein said mesenchymal stem cells are administered to an individual who has suffered myocardial infarction.
29. The method of claim 28 wherein said mesenchymal stem cells are administered directly to the heart.
30. The method of claim 28 wherein said the mesenchymal stem cells are administered systemically.
31. A method of regenerating myocardial tissue, said method comprising contacting said tissue with the composition comprising an isolated adult recombinant mesenchymal stem cell (rMSC), said rMSC comprising an exogenous nucleic acid operably linked to a promoter, wherein said nucleic acid expresses a therapeutically effective amount of a cell protective polypeptide, wherein the expression of said polypeptide is induced by a triggering agent or condition.
32. The method of claim 31, wherein the condition is hypoxia or oxidative stress.
33. The method of claim 31, wherein the agent is an antibiotic
34. The method of claim 33, wherein said antibiotic is tetracycline.
35. The method of claim 31, wherein the agent is an immunosuppressive.
36. The method of claim 35, wherein said immunosuppressive is rapamycin.
37. The method of claim 31, wherein the agent is a hormone receptor antagonist.
38. The method of claim 37, wherein said hormone receptor antagonist is mifepristone.
39. The method of claim 31, wherein the cell protective polypeptide is selected from the group consisting of an antioxidant enzyme protein, a heat shock protein, an anti-inflammatory protein, a survival protein, an anti-apoptotic protein, a coronary vessel tone protein, a pro-angiogenic protein, a contractility protein, a plaque stabilization protein, a thromboprotection protein, a blood pressure protein and a vascular cell proliferation protein.
40. The method of claim 31, wherein the subject is at risk of developing a condition characterized by aberrant cell damage.
41. The method of claim 31, wherein said aberrant cell damage is apoptotic cell death.
42. The method of claim 31, wherein said subject is at risk of developing stroke, myocardial infarction, chronic coronary ischemia, arteriosclerosis, congestive heart failure, dilated cardiomyopathy, restenosis, coronary artery disease, heart failure, arrhythmia, angina, atherosclerosis, hypertension, renal failure, kidney ischemia or myocardial hypertrophy.
43. The method of claim 21, wherein at least 20% of said injured myocardial tissue is regenerated.
44. A composition comprising an isolated mesenchymal stem cell comprising an exogenous nucleic acid encoding a tissue protective polypeptide, a oxygen sensitive regulatory element and a cell targeting element, wherein the expression of said polypeptide is regulated by said regulatory element
45. The composition of claim 44, wherein said oxygen sensitive regulatory element is a hypoxia response element.
46. The composition of claim 44, wherein said oxygen sensitive regulatory element is a oxidative stress response element.
47. The composition of claim 46, wherein said oxidative stress response element is a peroxidase promoter.
48. The composition of claim 44, wherein said cell targeting element is selected from the group consisting of -MHC, myosin light chain-2, troponin T.
49. The composition of claim 44, wherein the composition comprises vector selected from the group consisting of an adeno-associated virus vector, lentivirus vector retrovirus vector.
50. The composition of claim 44, wherein the composition comprises an adeno-associated virus vector.
51. A method of inhibiting apoptosis of engrafted cells in a mammal, said method comprising administering to said mammal a composition comprising an isolated mesenchymal stem cell comprising an exogenous nucleic acid encoding a polypeptide selected from the group consisting of: an extracellular superoxide dismutase polypeptide, a heme oxygenase polypeptide, and an Akt polypeptide, wherein said mammal is suffering from or at risk of developing a cardiac disorder.
52. The method of claim 51, wherein said cardiac disorder is selected from the group consisting of chronic coronary ischemia, arteriosclerosis, congestive heart failure, angina, atherosclerosis, and myocardial hypertrophy.
53. The method of claim 51, wherein said composition comprises an adeno-associated virus vector.
54. The method of claim 51, wherein the human heme oxygenase-1 nucleic acid is operatively linked to a promoter.
55. The method of claim 54, wherein said promoter is a human cytomegalovirus immediate early promoter.
56. The method of claim 51, wherein said human heme oxygenase-1 nucleic acid is operatively linked to a bovine growth hormone polyadenylation signal.
57. The method of claim 56, wherein said bovine growth hormone polyadenylation signal is flanked by the adeno-associated viral inverted terminal repeats.
58. The method of claim 51, wherein said composition is administered at a dose sufficient to increase survival of engrafted mesenchymal stem cell oxidative stress-induced cardiomyocyte cell death.
59. A method of increasing post-transplantation survival of engrafted cells in a mammal in a mammal, said method comprising administering to said mammal a composition comprising an isolated mesenchymal stem cell comprising an exogenous nucleic acid encoding a polypeptide selected from the group consisting of: an extracellular superoxide dismutase polypeptide, a heme oxygenase polypeptide, and an Akt polypeptide, thereby increasing survival of the engrafted cells.
60. The method of claim 59, mammal is at risk of a cardiac disorder.
61. The method of claim 59, wherein said cardiac disorder is selected from the group consisting of myocardial infarction, chronic coronary ischemia, arteriosclerosis, congestive heart failure, angina, atherosclerosis, and myocardial hypertrophy.
62. The method of claim 59, wherein said composition comprises an adeno-associated virus vector.
63. The method of claim 59, wherein the extracellular superoxide dismutase nucleic acid is operatively linked to a promoter.
64. The method of claim 63, wherein said promoter is a human cytomegalovirus immediate early promoter.
65. The method of claim 59, wherein said extracellular superoxide dismutase polypeptide nucleic acid is operatively linked to a bovine growth hormone polyadenylation signal.
66. The method of claim 65, wherein said bovine growth hormone polyadenylation signal is flanked by the adeno-associated viral inverted terminal repeats.
67. The method of claim 59, wherein said composition is administered at a dose sufficient to inhibit oxidative stress-induced cardiomyocyte cell death.
68. A method of treating a cardiac disorder, comprising identifying a mammal suffering from or at risk of developing said disorder and administering to said mammal a composition comprising an isolated mesenchymal stem cell comprising an exogenous nucleic acid expressing therapeutic amounts of a polypeptide selected from the group consisting of: an extracellular superoxide dismutase polypeptide, a heme oxygenase polypeptide, and an Akt polypeptide.
69. The method of claim 68, wherein said composition comprises an adeno-associated virus vector.
70. The method of claim 69, wherein the extracellular superoxide dismutase polypeptide nucleic acid is operatively linked to a promoter.
71. The method of claim 70, wherein said promoter is a human cytomegalovirus immediate early promoter.
72. The method of claim 68, wherein said extracellular superoxide dismutase nucleic acid is operatively linked to a bovine growth hormone polyadenylation signal.
73. The method of claim 72, wherein said bovine growth hormone polyadenylation signal is flanked by the adeno-associated viral inverted terminal repeats.
74. The method of claim 68, wherein said cardiac disorder is selected from the group consisting of myocardial infarction, chronic coronary ischemia, arteriosclerosis, congestive heart failure, dilated cardiomyopathy, restenosis, coronary artery disease, heart failure, arrhythmia, angina, atherosclerosis, hypertension, renal failure, kidney ischemia or myocardial hypertrophy, and stroke.
75. A cardioprotective agent comprising a recombinant adeno-associated viral vector comprising nucleotide encoding a extracellular superoxide dismutase polypeptide operatively linked to a human cytomegalovirus immediate early promoter.
76. The cardioprotective agent of claim 75, further comprising a bovine growth hormone polyadenylation signal.
77. The cardioprotective agent of claim 76, wherein said bovine growth hormone polyadenylation signal is flanked by the adeno-associated viral inverted terminal repeats.
78. A method for reducing scar formation in infarcted heart tissue, said method comprising contacting said tissue with the composition comprising an isolated adult recombinant mesenchymal stem cell (rMSC), said rMSC comprising an exogenous nucleic acid operably linked to a promoter, wherein said nucleic acid expresses a therapeutically effective amount of an anti-apoptotic gene.
79. A composition comprising an isolated adult recombinant mesenchymal stem cell (rMSC), said rMSC comprising an exogenous nucleic acid operably linked to a promoter, wherein said nucleic acid expresses a therapeutically effective amount of an anti-apoptotic gene.
80. The composition of claim 79, wherein the anti-apoptotic gene is selected from the group consisting of an Akt gene, an extracellular superoxide dismutase (ecSOD) polypeptide and a heme oxygenase gene.
81. A method of enhancing migration of a stem cell to an injured tissue, comprising increasing the amount of a stem cell polypeptide on the surface of said stem cell, wherein said stem cell polypeptide is selected from the group consisting of CXCR4, IL-6RA, IL-6ST, CCR2, Selel, Itgalb2, Itgamb2, Itga41b 1, Itga8b 1, Itga6b 1, and Itga9b 1.
82. The method of claim 81, wherein said cell is a bone marrow-derived stem cell.
83. The method of claim 81, wherein said cell is a mesenchymal stem cell.
84. The method of claim 81, wherein said method comprises introducing into said stem cell a nucleic acid encoding said receptor.
85. A method of enhancing engraftment of a stem cell to an injured tissue, comprising increasing the amount of an injury-associated polypeptide in said injured tissue, wherein said injury-associated polyeptide is selected from the group consisting of SDF1, IL-6, CCL2, Sele, ICAM-1, VCAM-1, FN, LN, and Tnc.
86. The method of claim 85, wherein said injured tissue is cardiac tissue.
87. The method of 85, wherein said injured tissue is ischemic myocardial tissue.
88. The method of claim 85, wherein said method comprises contacting said injured tissue with a nucleic acid encoding said injury-associated polypeptide.
89. The method of claim 85, wherein said method comprises contacting said injured tissue with said injury-associated polypeptide.
90. The method of claim 85, wherein said method comprises injecting said injury-associated polypeptide or a nucleic acid encoding said polypeptide directly into the myocardium.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A testing machine comprising:
a frame;
a roadway assembly comprising:
first roller;

a second roller;
an endless belt supported by and rolling on the first roller and the second roller; and
a carriage supporting the first roller and the second roller in spaced apart relation to cause a flat portion in the endless belt, the carriage being pivotally coupled to the frame to move relative to the frame about at least one axis that is perpendicular to an axis that is parallel to an axis of rotation of the first roller, the carriage including a bearing arranged to support an inner surface of the flat portion of the endless belt;
a spindle carriage having a spindle arranged to support a tire and wheel assembly, the spindle carriage movably mounted on the frame to move the spindle toward and away from the flat portion;
a drive operably coupled to the drive roller or the spindle; and
an actuator to control pivotal movement of the roadway assembly about said at least one axis.
2. The testing machine of claim 1 and wherein the endless belt includes a second flat portion and the carriage includes a second bearing arranged to support an inner surface of the second flat portion of the endless belt, and the machine further comprises a second spindle carriage having a second spindle arranged to support a second tire and wheel assembly, the second spindle carriage movably mounted on the frame to move the second spindle toward and away from the second flat portion.
3. The testing machine of claim 1 wherein said at least one axis comprises a steer axis perpendicular to the flat portion.
4. The testing machine of claim 1 wherein said at least one axis comprises a camber axis parallel to the flat portion.
5. The testing machine of claim 4 wherein the roadway assembly is configured to pivotally move relative to the frame about a steer axis that is perpendicular to the flat portion, and the machine further comprises a second actuator to control pivotal movement of the roadway assembly about the steer axis.
6. The testing machine of claim 1 and further comprising a bearing assembly pivotally connecting the carriage to the frame.
7. The testing machine of claim 6 wherein the roadway assembly is configured to pivotally move relative to the frame about a second axis that is perpendicular to the first-mentioned axis, and the machine further comprises a second actuator to control pivotal movement of the roadway assembly about the second axis.
8. The testing machine of claim 7 wherein the bearing comprises a spherical bearing.
9. The testing machine of claim 8 and further comprising a restraint configured to restrain motion of the roadway assembly about a third axis parallel to an axis of rotation of the first roller.
10. The testing machine of claim 7 wherein the bearing comprises a first bearing portion arranged to allow pivotal motion of the roadway assembly about the first axis and a second bearing portion arranged to allow pivotal motion of the roadway assembly about the second axis.
11. The testing machine of claim 1 and further comprising:
a device providing an output indicative of torque, power used, power generated, or forces; and
a controller operably coupled to the device and providing an output indicative of rolling loss of a tire mounted to the spindle.
12. A testing machine comprising:
a frame;
a roadway assembly comprising:
a first roller;
a second roller;
an endless belt supported by and rolling on the first roller and the second roller; and
a carriage supporting the first roller and the second roller in spaced apart relation to cause a first flat portion and a second flat portion in the endless belt, the carriage being pivotally coupled to the frame to move relative to the frame about at least one axis that is perpendicular to an axis that is parallel to an axis of rotation of the first roller, the carriage including a first bearing arranged to support an inner surface of the first flat portion of the endless belt and a second bearing arranged to support an inner surface of the second flat portion of the endless belt;
a first spindle carriage having a first spindle arranged to support a tire and wheel assembly, the first spindle carriage movably mounted on the frame to move the first spindle toward and away from the first flat portion;
a second spindle carriage having a second spindle arranged to support a tire and wheel assembly, the second spindle carriage movably mounted on the frame to move the second spindle toward and away from the second flat portion;
at least one drive operably coupled to the drive roller, the first spindle or the second spindle; and
an actuator to control pivotal movement of the roadway assembly about said at least one axis.
13. The testing machine of claim 12 and further comprising a bearing assembly pivotally connecting the carriage to the frame.
14. The testing machine of claim 13 wherein the roadway assembly is configured to pivotally move relative to the frame about a second axis that is perpendicular to the first-mentioned axis, and the machine further comprises a second actuator to control pivotal movement of the roadway assembly about the second axis.
15. The testing machine of claim 14 wherein the bearing comprises a spherical bearing.
16. The testing machine of claim 15 and further comprising a restraint configured to restrain motion of the roadway assembly about a third axis parallel to an axis of rotation of the first roller.
17. The testing machine of claim 13 wherein the bearing comprises a first bearing portion arranged to allow pivotal motion of the roadway assembly about the first axis and a second bearing portion arranged to allow pivotal motion of the roadway assembly about the second axis.
18. A method of tire testing comprising:
providing a frame; a roadway assembly comprising: an endless belt; and a carriage supporting the endless belt for rotation on the carriage and providing a flat portion in the endless belt, the carriage being pivotally coupled to the frame to move relative to the frame about at least one axis, the carriage including a bearing arranged to support an inner surface of the flat portion of the endless belt; a spindle carriage having a spindle supporting a tire and wheel assembly, the spindle carriage movably mounted on the frame to move the spindle toward and away from the flat portion; a drive operably coupled to the roadway assembly or the spindle; and an actuator to control pivotal movement of the roadway assembly about said at least one axis;
operating the actuator to pivot the roadway assembly relative to the frame and about the axis to obtain a desired position; and
operating the drive to cause rotation of the tire and wheel assembly.
19. The method of claim 18 and comprising calculating a value indicative of rolling loss for the tire.
20. The method of claim 18 wherein the roadway assembly is configured to pivotally move relative to the frame about a second axis that is perpendicular to the first-mentioned axis, and the machine further comprises a second actuator to control pivotal movement of the roadway assembly about the second axis, and the method further comprises the testing machine further comprises operating the second actuator to pivot the roadway assembly relative to the frame and about the second axis to obtain the desired position.
21. The method of claim 20 and comprising calculating a value indicative of rolling loss for the tire.
22. A testing machine comprising:
a frame;
a roadway assembly comprising:
an endless belt; and
a carriage supporting the endless belt for rotation on the carriage and providing a flat portion in the endless belt, the carriage being pivotally coupled to the frame to move relative to the frame about at least one axis, the carriage including a bearing arranged to support an inner surface of the flat portion of the endless belt;
a spindle carriage having a spindle arranged to support a tire and wheel assembly, the spindle carriage movably mounted on the frame to move the spindle toward and away from the flat portion;
a drive operably coupled to the roadway assembly or the spindle; and an actuator to control pivotal movement of the roadway assembly about said at least one axis.
23. The testing machine of claim 22 wherein the roadway assembly is configured to pivotally move relative to the frame about a second axis that is perpendicular to the first-mentioned axis, and the machine further comprises a second actuator to control pivotal movement of the roadway assembly about the second axis.